Haleon (LON:HLN) Sets New 1-Year Low – Time to Sell?

Haleon plc (LON:HLN)’s stock price reached a new 52-week low on Tuesday . The stock traded as low as GBX 325 and last traded at GBX 327, with a volume of 137770469 shares changing hands. The stock had previously closed at GBX 327.10.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Jefferies Financial Group lowered their price target on Haleon from GBX 450 to GBX 400 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Berenberg Bank reaffirmed a “buy” rating and issued a GBX 512 price target on shares of Haleon in a report on Thursday, April 30th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a GBX 370 price target on shares of Haleon in a report on Thursday, April 30th. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on Haleon from GBX 340 to GBX 335 and set a “buy” rating on the stock in a report on Thursday, January 22nd. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Haleon presently has an average rating of “Moderate Buy” and an average target price of GBX 398.67.

Haleon Trading Up 0.6%

The firm has a 50-day moving average of GBX 364.74 and a 200-day moving average of GBX 370.45. The company has a debt-to-equity ratio of 52.26, a quick ratio of 0.93 and a current ratio of 0.92. The firm has a market capitalization of £29.24 billion, a P/E ratio of 17.78, a price-to-earnings-growth ratio of 1.49 and a beta of 0.25.

Haleon (LON:HLN) last posted its quarterly earnings results on Thursday, February 26th. The company reported GBX 18.60 earnings per share (EPS) for the quarter. Haleon had a return on equity of 6.43% and a net margin of 12.59%. On average, equities research analysts anticipate that Haleon plc will post 19.5033282 EPS for the current fiscal year.

Insider Buying and Selling at Haleon

In other news, insider Brian McNamara sold 63,012 shares of Haleon stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of GBX 368, for a total value of £231,884.16. Corporate insiders own 0.01% of the company’s stock.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.